CURRICULUM VITAE GREGG ROUNTREE EURE, M.D., FACS

Transcription

CURRICULUM VITAE
GREGG ROUNTREE EURE, M.D., FACS
PERSONAL INFORMATION
Home Address:
1301 Kildeer Court
Virginia Beach, Virginia 23451
EuresVB@aol.com
Work Address:
Sentara Medical Group - Urology of Virginia, P.C.
August 1991-Present
Office Address:
1200 First Colonial Road, Suite 100
(757) 481-3556 Office Phone
(757) 496-3865 Office Fax
Date of Birth:
December 1,1959
Hampton, VA
EDUCATION
1977-1981
University of Virginia, B.A.
Charlottesville, Virginia
(Graduated with High Distinction. GPA 3.6)
1981-1985
Medical College of Virginia
Richmond, Virginia
(Ranked in top third of class)
1985 - 1987
Resident, General Surgery
Medical College of Virginia, Richmond, Virginia
1988 - 1991
Resident, Urology
Eastern Virginia Graduate School of Medicine, Norfolk, Virginia
PROFESSIONAL EXPERIENCES
August, 1991Present
Sentara Medical Group - Urology of Virginia, P.C.
1200 First Colonial Road, Suite 100
August, 1991Present
Eastern Virginia Medical School
Assistant Professor of Urology
January 2005Present
Research Chairman
Urology of Virginia Research Department
July 1990June 1991
Eastern Virginia Medical School
Instructor Urology
Chief Resident, EVMS
Gregg R. Eure, M.D.
2
July, 1987June, 1988
Emergency Room Physician
Sentara Medical Care Centers
Norfolk, Virginia
(Part-time)
October, 1986July, 1987
Emergency Room Physician
Coastal Physician Services
(Part-time)
May, 1983July, 1987
Extern
Richmond Metropolitan Hospital
Richmond, Virginia
December, 1983-1985
Extern
Johnston-Willis Hospital
Richmond, Virginia
PERSONAL MILESTONES
Medical School Admissions Tour Guide
Big Brother Program
Basketball Coach, Tandem Private High School
Extensive intramural sports involvement
Disneyworld Marathon
Master Sommelier, level 1
HOSPITAL CREDENTIALS
Sentara Virginia Beach General Hospital
Sentara Bayside Hospital
Sentara Leigh Hospital
Sentara Norfolk General
Sentara Virginia Beach Ambulatory Surgery Center
Chesapeake General Hospital
Surgery Center of Chesapeake
HONORS AND ACCREDITATION
2007 Hampton Roads Magazine “Best Doc for Men”, Urology
AUA Young Leadership Recipient
Physician's Recognition Award
2003 Hampton Roads Magazine “Best Doc for Men”, Urology
Best Surgical Teacher (Awarded by the residents)
Florence Smith Medical Merit Scholarship of the Norfolk Foundation
Chi Psi Graduate Fellowship Award
Member Alpha Epsilon Delta, National Premedical Honor Society
Dean's List UVA, All Semesters
3
Gregg R. Eure, M.D.
SOCIETIES AND MEMBERSHIPS
American Association of Clinical Urologists
American Medical Association
American Urological Association
Diplomat of the American Board of Urology
Diplomat of the National Board of Medical Examiners
Fellow of the American College of Surgeons
Medical Society of Virginia
Seaboard Medical Association
Society of University Urologists
Tidewater Urological Society
Virginia Beach Medical Society
Virginia Chapter College of Surgeons
Virginia Urological Society
COMMITTEES
Board of Directors, Mid-Atlantic American Urology Association
OR/PAR (Operating Room/Post Anesthesia Recovery) Committee, Sentara Virginia Beach General Hospital
Cancer Committee, Sentara Virginia Beach General Hospital
Surgery Privileges SubCommittee, Sentara Virginia Beach General Hospital
Tumor Board, Presenter, Sentara Virginia Beach General
Member, Board of Directors, Urology of Virginia
Director of Clinical Research, Devine Tidewater Urology
Chairman, Organizational, Development, Marketing Committee, Urology of Virginia
Management Committee, Devine Tidewater Urology
Member, Urology of Virginia Board
CONSULTANT/PRECEPTORSHIPS/TRAINING
Physician trainer for GreenLight, Photoselective Vaporization of Prostate (PVP)
Gerson Lehrman Consultation
Site Evaluator, Boston Scientific Prolieve Microwave System
CERTIFICATIONS
Certified Trainer For GreenLight Photoselective 2003
Recertification American Board of Urology
Certified Healthtronics Lithotron Kidney Lithotripter
Certified Trainer for Indigo LaserOptic
Certified Trainer for Scalpeless Vasectomies
American Board of Urology Certification
Certified Candela MDF-2000 Lasertripter
Certified in Extra Corporeal
Shockwave Lithotripsy-Lithostar
Certified in Laser Surgery
National Medical Boards
Advanced Trauma Life Support
Advanced Cardiac Life Support
2003
2001
1999
1995
1995
1993
1991
1991
1986
1986
1984
4
Gregg R. Eure, M.D.
PROFESSIONAL ACTIVITIES
AUA Health Policy Council
Advisor and Speaker for GSK
Advisor and Speaker for Boehringer Ingelheim: BPH
Advisory Board for Organon
Consultant for Man to Man Prostate Cancer Counseling Program (sponsored through the ACS)
Consultant and Speaker, American Medical Systems
Consultant Astra-Zenica
Consultant, Lilly-ICOS
Consultant, Ortho Urology
Coordinator, Prostate Ultrasound Conference, Dr. William Cooner, SNGH
Program Director and Speaker "Urology Update Conference" , 1998, 2001, 2005
Faculty Leader for Resident Journal Club
Scientific Advisor for Thermatrx: Trans-urethral Microwave Therapy (TUMT) Study
Exam Proctor, Residents In-Service Exam, Eastern Virginia Medical School
Virginia District #2 Advisor, Committee on Applicants for the American College of Surgeons
Secretary/Treasurer, Tidewater Urological Society
President, Tidewater Urological Society
Supervising Physician for Physician Assistant, Devine Tidewater Urology
Supervising Physician for Physician Assistant, Sentara Virginia Beach General and Sentara Bayside
President & Director of the Foundation for Specialized Surgery
Hampton Roads Lithotripsy Board
ACADEMIC APPOINTMENTS
Educational Director for Urology Residency Program at Sentara Virginia Beach General Hospital, 2002Present
Assistant Professor of Clinical Urology, Eastern Virginia Graduate School of Medicine, Norfolk, Virginia,
July 1, 1992- Present
Instructor, Department of Urology, Eastern Virginia Graduate School of Medicine, Norfolk, Virginia,
August 1991-July 1992
ACADEMIC PRESENTATIONS
"UTI's", EVMS, Norfolk, VA, October 21, 1992
"The Advances of Urologic Surgery", Sentara Leigh Hospital, December 9,1992
"UTI's", EVMS, Norfolk, Virginia, October 13,1993
"Prostate Cancer: Use of Markers, Ultrasound, and Laparoscope", Virginia Chapter, American College
of Surgeons, Hot Springs, Virginia, April 29-May 1, 1994
"BPH", Merck Pharmaceutical, Norfolk, Virginia, June 7, 1994
New Advances in BPH and Prostate Cancer, Urology Update for Primary Care Physicians, Virginia
Beach, Virginia, October 8, 1994
“BPH Update”, Filipino Medical Association, Norfolk, Virginia, July 9, 1995
Management of Kidney Stone Disease, Virginia Beach, Virginia, July 13, 1995
5
Gregg R. Eure, M.D.
Prostate Cancer and Other Neoplasms of the Genitourinary Tract, February 26-27, 1996
“Current Management Trends in BPH”, Guest Speaker, Maryland Academy of Medicine, Ocean City, MD
June 11-12, 1998
“New Treatments for Erectile Dysfunction”, Virginia Beach General Hospital Grand Rounds,
August 12, 1998
“Vasectomy and No-Scalpel Technique” Resident Lecture, EVMS, April 29, 1999
“Sexual Vigor”, Anti-aging seminar EVMS, Sentara, March 7, 1998
“Erectile Dysfunction”, WTKR Channel 3 News, April 28, 1998
“BPH”, Guest Speaker Symposium on Urology, Vencor Hospital, Arlington, VA May 9, 1998
“BPH”, Grand Rounds CME Committee, Virginia Beach General Hospital, May 18, 1998
“BPH”, Grand Rounds Virginia Beach General Hospital, May 19, 1998
“Diagnosis and Treatment of Erectile Dysfunction”, Filipino Medical Association, September 21, 1998
“Current Treatment Options for Prostatitis and BPH”, Sentara Bayside Hospital, October 14, 1999
“BPH: Pills, Laser, Cut or Cook”, Urology Update for Primary Care, Virginia Beach, Virginia, October 16,
1999
“Viagra – One Year Later”, Primary Care Conference, Sentara Virginia Beach General
(sponsored by Pfizer), January 27, 2000
"Periurethral Prostatic Microwave Thermotherapy Using the Thermatrx TMX-2000: Follow up of a
Randomized, Blinded Study Comparing TUMT with a Sham Procedure in Patients with BPH" ,
Southeastern Section AUA April 2, 2000
”Advances in BPH Treatment” – Boehringer Ingelheim, Virginia Beach, VA – May 20, 2000
“Periurethral Prostatic Microwave Thermotherapy Using the Thermatrx TMX-2000; Follow up of a
Randomized, Blinded Study Comparing TUMT with a SHAM Procedure in Patients with BPH” – Oral
Abstract, Northeastern Section of the AUA, Pittsburgh, Pennsylvania, September 14-17, 2000.
Talk “Urologic Infectious Diseases”, Primary Care Conference, Sentara Virginia Beach General,
September 21, 2000
“Periurethral Prostatic Microwave Thermotherapy Using the Thermatrx TMX-2000; Follow up of a
Randomized, Blinded Study Comparing TUMT with a SHAM Procedure in Patients with BPH” – Oral
Abstract, Mid-Atlantic Section of the AUA, Rio Grande, Puerto Rico, October 15-18, 2000.
Talk “BPH: A Primary Care Perspective”, Sponsored by MERCK, Virginia Beach, Virginia,
October 21, 2000
Talk “A Urologist’s Choice of Treatment for BPH” Merck, Virginia Beach, Virginia, January 18, 2001
6
Gregg R. Eure, M.D.
Talk “Genitourinary Infections Hospital and Outpatient Settings” – Ortho-McNeil – Virginia Beach, Virginia,
June 19, 2001
Talk “UTI’s and Prostatitis” – Ortho-McNeil – Virginia Beach, Virginia, July 13, 2001
Northeastern Section American Urological Association Annual Meeting, Boca Raton, FL, December 1316, 2001, Presentation on BPH and Minimally Invasive Therapy
BPH Regional Speaker Meeting – Dallas, TX, January 18 – 19, 2002
“Recent Advances in Overactive Bladder”, Primary Care Conference, Sponsored by Sentara Virginia
Beach General Hospital, Virginia Beach, VA, February 21, 2002
American Lithotripsy Society, Urology Society of America, Combined Annual Meetings, Hyatt Regency
Lake Las Vegas Resort, Henderson, Nevada, March 14-17, 2002, Presentation on BPH and Update on
Minimally Invasive Therapy
Thermatrx, Atlanta, GA ~ November 21-22, 2002
“Update on Benign Prostatic Hypertrophy” by Dr. Gregg Eure, Sentara Virginia Beach General Hospital,
Grand Rounds, Virginia Beach, VA, December 17, 2002
URO Speaker Meeting, Los Cabos, Mexico ~ March 13-16, 2003 [Program Chair/Director]
Virginia Academy of Physician Assistants Summer CME Conference, Virginia Beach, Virginia, Summer
2003
“Management of Prostate Disorders for the Primary Care Physician – Eastern Virginia Medical School
Norfolk, VA June 4, 2003
TherMatrx Peer to Peer Meeting Columbus, OH June 9, 2003
TherMatrx Peer to Peer Meeting Buffalo, NY June 10 – 11, 2003
“Update on Benign Prostatic Hypertrophy” Virginia Beach, VA June 17, 2003
BPH Disease Progressions: New Treatment Paradigms – GlaxoSmithKline – August 2003
Benign Prostatic Hyperplasia, Primary Care Conference, Sentara Virginia Beach General Hospital,
Virginia Beach, VA, August 14, 2003
TherMatrx Peer to Peer Meeting Memphis, TN August 21 – 22, 2003
“Current Trends in the Management of Benign Prostatic Conditions”, Expert Faculty Speaker, DAW
Communications, Norfolk, Virginia, September 30, 2003
Prostatitis and Genital Urinary Tract Infection, Primary Care Conference, Sentara Virginia Beach General
Hospital, Virginia Beach, VA, September 11, 2003
“Prostate Cancer Update – 2003, Sentara Virginia Beach General Hospital, September 18, 2003
7
Gregg R. Eure, M.D.
“BPH-A Concise Review of Therapies”, Sentara Bayside Hospital, Virginia Beach, VA, October 23, 2003
New York Section, American Urological Association, Greece, October 12-17, 2003
Talk: Transurethral Microwave Thermotherapy (TUMT) Using The Thermatrix TMx2000TM Durability
Exhibited in a Study Comparing TUMT with a Sham Procedure in Patients With Benign Prostatic
Hyperplasia (BPH)
“Management of BPH”, by Dr. Gregg Eure, Richmond Urologic Forum, Jefferson Hotel, Richmond, VA,
February 21, 2004
URO 2004, Key Biscayne, FL ~ March 4-7, 2004
“New Advances in the Treatment of Erectile Dysfunction” by Dr. Gregg Eure, Primary Care Conference,
Sentara Virginia Beach General Hospital, Virginia Beach, VA, March 11, 2004
“The Changing Landscape in the Treatment of Erectile Dysfunction”, by Dr. Gregg Eure, Lilly ICOS
Lecture Series, Virginia Beach, Virginia, March 17, 2004
“Treatment Modalities of Erectile Dysfunction” by Dr. Gregg Eure, Portsmouth Academy of Medicine
General Meeting, Portsmouth, Virginia, May 3, 2004
“Prostate Cancer: Hormone Therapy” by Dr. Gregg Eure, Cancer Conference, Sentara Virginia Beach
General Hospital, Virginia Beach, Virginia, July 6, 2004
“Prostate Cancer Update-2004”, Sentara Virginia Beach General Hospital, September 9, 2004
Managing BPH: A Primary Care Challenge for the 21st Century, Cary, NC October 20, 2004
“Benign Hyperplasia: Men’s Health Challenge for the 21st Century”, Eastern Virginia Medical School,
November 17, 2004
Annual Kimbrough Urological Seminar, Sheraton Waikiki Hotel, Honolulu, HI, January 16, 2005,
Presentation TUMT and Sexual Function
ForTec Medical Systems, GreenLight PVP Workshop: BPH Management, Portsmouth Naval Medical
Center, Portsmouth, VA, February 1, 2005
State of the Art Urology, 2005: BPH A Concise Review of Therapies, September 2005
”Bladder Matters: New Perspectives for Pelvic Management”, Ortho-Urology and Ditropan XL, Fairfax,
VA, August 11, 2005
Men’s Health Seminar: Managing BPH & GreenLight PVP, Norfolk, VA, December 8, 2005
“Advanced Concept Summit on PVP”, Atlanta, GA ~ February 7, 2006 (LASERSCOPE)
Treatment of Enlarged Prostate “Laser PVP – The New Gold Standard” February, 16, 2006 SVBGH
“Advanced Concept Summit on PVP”, Washington, D.C. ~ June 7, 2006 (LASERSCOPE)
8
Gregg R. Eure, M.D.
“Current Trends in the Treatment of BPH: Minimally Invasive Thermotherapy”, Boston, MA ~ June 24,
2006 (TherMatrx)
2006-2007 AUA Leadership Program, Linthicum, MD ~ July 28-30, 2006
“Minimally Invasive and Laser Therapies for BPH” State-of-the-Art Lecture, Northeastern Section of AUA
Annual Meeting, Ottawa, Canada ~ September 7, 2006 (Boehringer-Ingelheim)
“Understanding the ED Treatment Paradigm”, Newport News, VA ~ September 20, 2006
“Prostate Cancer Update – 2006”, Sentara Virginia Beach General Hospital ~ September 28, 2006
“Understanding the ED Treatment Paradigm” (Cialis), Galax, VA ~ October 3, 2006
Corporate Presentation on Thermatrx and GreenLight (AMS), Minneapolis, MN ~ October 23, 2006
“Current Trends in the Treatment of BPH: Minimally Invasive Thermotherapy”, Baltimore, MD ~
November 4, 2006 (AMS)
AMS Course, Washington, D.C. ~ November 17, 2006
PVP/HPS Training, Virginia Beach, VA (AMS) ~ November 29, 2006
PVP/HPS Training, Newport News, VA (AMS) ~ December 12, 2006
“Current Trends in the Treatment of BPH: Minimally Invasive Thermotherapy”, Costa Mesa, CA ~ January
26-27, 2007 (AMS)
“Current Trends in Treatment of BPH: Minimally Invasive Thermotherapy”, Phoenix, AZ ~ March9-10,
2007 (AMS)
TherMatrx TMX3000 Meeting, Chicago, IL (AMS) ~ March 23-24, 2007
PVP/HPS Training, San Fransico, CA (AMS) ~ April, 18. 2007
HPS/TherMatrx Peer to Peer Presentation (AMS) Washington, DC ~ May 2-3, 2007
HPS Peer to Peer Presentation (AMS) Albany, NY ~ May 31, 2007
PVP/HPS Training, Albany, NY (AMS) ~ June 1, 2007
“Identifying and Managing Men with Enlarge Prostate (EP): Targeting Symptoms at Their Source”,
Virginia Beach, VA (GSK) ~ August 1, 2007
FLOMAX Educational Speaker Presentation, Virginia Beach, VA (BI) ~ August 16, 2007
Avodart Advisory Board, Washington, DC (GSK) ~ August 24, 2007
9
Gregg R. Eure, M.D.
Virginia Beach, VA (GSK) ~ August 31, 2007
FLOMAX Educational Speaker Presentation, Virginia Beach, VA (BI) ~ September 6, 2007
PVP/HPS Training, Lebanon, NH (AMS) ~ September 13, 2007
Virginia Beach, VA (GSK) ~ September 17, 2007
TMX 3000 Peer to Peer Presentation, Richmond, VA (AMS) ~ September 19, 2007
TherMatrx Training, San Francisco, CA (AMS) ~ October 12-13, 2007
“BPH Expert Panelist” Minimally Invasive Therapy for BPH, Miami, FL (AMS) ~ January 9, 2008
PVP/HPS Training, London, Ontario, Canada (AMS) ~ January 23-25, 2008
PVP/HPS Training, London, Ontario, Canada (AMS) ~ February 20-21, 2008
“Cialis Dosing Options: Which one is right for your patients?”, Lebanon, VA (Lilly) ~ April 9-10, 2008
“Cialis Dosing Options: Which one is right for your patients?”, Blacksburg, VA (Lilly) ~ April 28, 2008
GreenLight HPS Advanced Concepts Workshop, Chicago, IL (AMS) ~ May 2-3, 2008
“Vaporize Your Patient’s BPH Concerns With The GreenLight Laser”, Virginia Beach, VA ~ June 10,
2008
Family Medicine Review Course “BPH & Prostate Screening” Virginia Beach, VA (EVMS) ~ June 18, 2008
MIS Conference, Williamsburg, VA ~ August 15-17, 2008
PVP/HPS Training, Toronto, Ontario, Canada (AMS) ~ August 20-21, 2008
Grand Rounds at University of Maryland , Washington, DC (AMS) ~ September 17-18, 2008
Grand Rounds at University of Miami, Miami, FL (AMS) ~ October 1-3, 2008
MEDICAL MEETINGS
Benign Prostatic Hypertrophy Speakers Conference, Hilton Head Island, South Carolina, August 30-31,
1991
Prostate Cancer and Urothelial Cancer, Stouffer Hotel, Orlando, Florida, October 3-5, 1991
Treatment of Prostate Cancer, Norfolk, Virginia, December 7, 1991
New Approaches in the Treatment of Prostate Cancer and Benign Prostatic Hypertrophy, December
7,1991
10
Gregg R. Eure, M.D.
Annual Residency Workshop, Lewis Hall, Auditorium, EVMS, Norfolk, Virginia, April 25, 1992
Seaboard Urological Association-Annual Meeting, Nags Head, North Carolina, June 18-20,1992
Ultrasound Conference, Norfolk, Virginia, June 27-28, 1992
Mid-Atlantic Section, American Urological Association, Williamsburg, Virginia, September 20-23, 1992
Intravesical Alpha 2b-Interferon, Newark, New Jersey, October 9, 1992
Seaboard Urological Association-Annual Meeting, Nags Head, North Carolina, June 17-20, 1993
AUA Research Conference on Immunology and Inflammation, Houston, Texas, August 20-23, 1993
Mid-Atlantic Section, American Urological Association, West Palm Beach, Florida, September 18-22,
1993
Nocturnal Enuresis: New Perspectives for the 90's, Rancho Mirage, California, October 1-3, 1993
Annenberg Educational Symposium-PNE: New Perspectives for the Nineties, November 5, 1993
East Coast Symposium on Endoscopic Surgery, SLH, Norfolk, Virginia, November 6,1993
AUA Conference on Prostate Cancer, Washington D.C., December 3-5,1993
4th International Conference on BPH/Prostate and Urothelial Cancer, Orlando, Florida, March 10-12,
1994
New Advances in BPH and Prostate Cancer, Urology Update for Primary Care Physicians, Virginia
Beach, Virginia, October 8, 1994
Mid-Atlantic Section, American Urological Association, San Francisco, California, May 16-19, 1994
Urotrend 2000, Washington, D.C., July 16, 1994
Southwest Oncology Group PIVOT Study Meeting, Minneapolis, Minnesota, August 16-18, 1994
Liarozole Investigators Meeting, Chicago, Illinois, September 30- October 1,1994
Program Director, "New Advances in BPH and Prostate Cancer" Conference, October 8, 1994
New Developments in Prostate Cancer Management, Pebble Beach, California, January 11-13 1995
Virginia Urological Society Meeting Williamsburg, Virginia, May 5-7, 1995
Visiting Faculty in Interferon' Meeting, Rancho Mirage, California, June 2-3, 1995
11
Gregg R. Eure, M.D.
A Commitment to Urology: Therapeutic Innovations in BPH and Prostate Cancer, Williamsburg, Virginia,
June 8-10, 1995
Mid-Atlantic Section, American Urological Association, Southampton, Bermuda, September 17-20, 1995
American Society for Reproductive Medicine, Seattle, Washington, October 6-12, 1995
SWOG/Society of University Urologists Meeting, New Orleans, Louisiana, October 25-28, 1995
PLESS Investigator's Meeting, San Diego, California, November 25-29, 1995
Partners in Urologic Surgery, Chicago, Illinois, August 10-11, 1996
Mid-Atlantic, Washington, D.D., October 27-30, 1996
Zeneca Speaker Support Prostate Cancer Update meeting, Litchfield Park, Arizona, January 16-19, 1997
Mid-Atlantic Section, American Urological Association, New Orleans, LA April 12-17, 1997
Investigators Meeting Merck PLESS Program, San Diego, CA, May 31-June 2, 1997
Hoechst Marion Roussell, Inc. Nilandron FLARE Protocol meeting, Naples, Florida, October 5-7, 1997
Viagra Speakers Bureau Meeting, Lake Buena Vista, Florida, February 20-22, 1998
Schering Oncology Meeting, Montreal, Quebec, February 27 - March 1, 1998
Mid-Atlantic Section, American Urological Association, San Diego, CA May 29-June 4, 1998
THERMATRX Investigator’s meeting, New York, New York, September 3-4, 1998
Prostate Cancer: New Strategies for Diagnosis, Staging and Management, Chicago, IL, July 10-12, 1998
Mid-Atlantic Section, American Urological Association, Palm Beach, FL October 3-7, 1998
SWOG, Annual Meeting, San Antonio Texas, October 20-24, 1998
Prostate Cancer: New Strategies for Diagnosis, Staging and Management, Medical Education
Collaborative, Miami, FL November 6, 1998
Levaquin Urology Speaker’s Training Program, Arizona Biltmore Resort & Spa, Phoenix, Arizona,
January 14-17, 1999
12
Gregg R. Eure, M.D.
THERMATRX Investigator’s meeting, Chicago, IL February 26, 1999
Southeast Section, AUA, Charleston, SC, March 19-23, 1999
New Frontiers in the Diagnosis and Treatment of Prostate Diseases, Medical Education Collaborative,
Washington, DC April 9, 1999
National Urology Consultants’ Meeting, Merck & Co., Orlando, FL, April 16-18, 1999
American Urological Association Annual Meeting, Dallas, TX May 1-6, 1999
AUA: Advances in BPH Research Conference (by invitation only), Houston, TX, July 30-August 1, 1999
Mid-Atlantic Section, American Urological Association, Hilton Head, SC October 3-6, 1999
AUA Urolithiasis Update, Washington, DC, December 10 – 12, 1999
National Urology Consultants Meeting, Merck & Co., Phoenix, AZ, February 25-27, 2000
URO2000, Speaker’s Meeting Boehringer Ingelheim, Cancun Mexico, March 16-19, 2000
American Urological Association Annual Meeting, Atlanta, GA, April 29-May 4, 2000
Zeneca Advisory Board Meeting, “Current Practice Trends in the Treatment of Prostate Cancer”, Ponte
Verda, Florida, June 8 – 11, 2000
THERMATRX Investigator’s meeting, Providence, R.I., July 28 – 30, 2000
“Radiology: Today and Tomorrow” by Dr. John O’Neil, Grand Rounds, Sentara Virginia Beach General
Hospital, Virginia Beach, VA, February 27, 2001
THERMATRX Investigator’s meeting, Park City, Utah, February 8-11, 2001
“Prostate Cancer”, Grand Rounds, Sentara Virginia Beach General Hospital, Virginia Beach, VA, March
6, 2001
URO2001, Speaker’s Meeting Boehringer Ingelheim, Santa Barbara, California, April 26-29, 2001
Erectile Dysfunction Preceptorship, Boston, MA Program May 3 – 4, 2001
American Urological Association Annual Meeting, Anaheim, California, June 2-7, 2001
“Adjuvant and Neoadjuvant Hormonal Therapies”, Norfolk, VA, June 13, 2001
RiskAware for Physicians, Independent Study Course, Medical Risk Management, Inc., July 10, 2001
13
Gregg R. Eure, M.D.
Cancer Conference, Sentara Virginia Beach General Hospital, Virginia Beach, VA, November 6, 2001
Flomax Advisory Board Meeting, Four Seasons Hotel, Philadelphia, PA, October 26 –28, 2001
Northeastern Section American Urological Association Annual Meeting, Boca Raton, FL, December 1316, 2001.
TherMatrx/American Medical Systems SAB Meeting Scottsdale, AZ January 10 – 13 2002
American Lithotripsy Society, Urology Society of America, Combined Annual Meetings, Hyatt Regency
Lake Las Vegas Resort, Henderson, Nevada, March 14-17, 2002.
URO2002, Speaker’s Meeting Boehringer Ingelheim, Los Cabos, Mexico, March, 2002, Program
Chairman
“Power Point For Physicians”, Eastern Virginia Medical School, Norfolk, VA, April 27, 2002
American Urological Association Annual Meeting, Orlando, FL, May 24-30, 2002
“Recent Advances in the Management of Prostate Cancer”, Washington, DC, August 16, 2002
Mid-Atlantic American Urological Association Annual Meeting, Baltimore, Maryland, October 9, 2002
“New Techniques in Endourology: Laser, PCNL and Ureteroscopy”, Crowne Plaza, New York, NY,
December 7, 2002
Flomax Advisory Board Meeting 2003 Key Biscayne, FL January 10 – 11, 2003
TherMatrx Peer to Peer Meeting, Philadelphia, PA, January 22, 2003
TherMatrx Peer to Peer Meeting, Washington, DC, January 23, 2003
Urology Oncology Meeting, Tucson, AZ ~ February 16-19, 2003
GlaxoSmithKline and Avodart National Speaker Training Meeting, Denver, CO, March 7 – 9, 2003
American Urological Association Annual Meeting, Chicago, IL, April 26-May 1, 2003
TherMatrix Peer to Peer Meeting Philadelphia, PA, May 19, 2003
TherMatrx Peer to Peer Meeting Portland, OR, June 24, 2003
TherMatrx Peer to Peer Meeting San Francisco, CA June 25-26, 2003
TherMatrx Peer to Peer Meeting Pittsburg, PA, July 16, 2003
TherMatrx Peer to Peer Meeting, Orlando, FL July 17 – 18, 2003
GlaxoSmithKline Reduce Investigators Meeting, Hyatt Regency McCormick Place, Chicago, IL
July 23 –24, 2003
14
Gregg R. Eure, M.D.
BPH & Beyond Key Opinion Leader, Scientific Session, Waldorf-Astoria, New York, NY, October 28-29,
2003
Flomax Advisory Board Meeting, The Ritz Carlton Cancun, Mexico January 16 – 17, 2004
SBCD Start Up Meeting, Hyatt Regency Hill Country, San Antonio, TX, February 22-24, 2004
TherMatrx Peer to Peer Meeting, Atlanta, GA, April 15, 2004
GreenLight PVP Training Course, Salem, VA, April 23, 2004
GreenLight PVP Training Course, Fredericksburg, VA, May 18, 2004
“TherMatrx Dose Optimized Thermotherapy, A Different Kind of TUMT” by Dr. Gregg Eure, 3rd IAUA
Scientific & Educational Program, Hilton, San Francisco, California, May 9, 2004
American Urological Association Annual Meeting, San Francisco, CA, May 8-13, 2004
TherMatrx/American Medical Systems Dose Optimized Thermotherapy Training, Presenter 7-12- “Data
Review” and “A Physician’s Perspective”, Minneapolis, MN, July 11-12, 2004
The New York Academy of Medicine Conference, New York, NY September 29, 2004
Lilly ICOS Investigators Meeting, Phoenix, AZ October 1-2, 2004
GreenLight PVP Training Seminar, Reston, VA, February 8, 2005
Sanctura UroBureau Faculty Meeting, Scottsdale, AZ, February 18 – 19, 2005
QLT Investigator Meeting, New Orleans, LA ~ April 8-10, 2005
TherMatrx Peer to Peer Meeting Baltimore, MD May 20, 2005
TherMatrx Peer to Peer Meeting, New York, NY June 9, 2005
Boehringer Ingelheim Flomax Advisory Board Meeting New York, NY, June 11, 2005
ForTec Medical Systems, GreenLight PVP Workshop: BPH Management, Washington, DC, June 28,
2005
TherMatrx Peer to Peer Meeting, New York, NY, August 25, 2005
Prostate Screenings, Sentara Virginia Beach General Hospital, September 21, 2005
GlaxoSmithKline Avodart Advisory Board Meeting, Sheraton Hotel, Philadelphia, PA, December 2, 2005
GlaxoSmithKline Avodart Speaker Training Program Las Vegas, NV March 3 – 4, 2006
National Advisory Board, New York City, NY ~ May 5-6, 2006 (Boehringer-Ingelheim)
AUA Annual Meeting, Atlanta, GA ~ May 19-24, 2006
15
Gregg R. Eure, M.D.
GSK Investigator Meeting, Chicago, IL ~ June 15-16, 2006
Mulidisciplinary Approach to Prostate Cancer in 2006, Dr. Leonard Gomella ~ June 19, 2006
“LVHG Start up Meeting”, Cialis Trial, Dallas, TX ~ August 10-12, 2006 (Lilly)
“Pediatric Urology and Male Infertility”, Dr. Stuart Howards ~ September 26, 2006
“Intersex”, Dr. Stuart Howards ~ September 26, 2006
“Maintenance of Certification”, Dr. Stuart Howards ~ September 27, 2006
Mid-Atlantic AUA, Washington, D.C. ~ October 12-14, 2006
Flomax National Advisory Board, Miami, FL ~ December 8-9, 2006
Spectrum Investigator Meeting, Fort Worth, TX ~ January 12-13, 2007
“Hereditary Colon Cancer Syndromes”, Dr. Davis Stockwell III ~ March 20, 2007
Joint Advocacy, Washington, DC ~ March 24-27, 2007
Spectrum Investigator Meeting, Phoenix, AZ ~ March 30-April 1, 2007
“Pediatric Dermatology Potpourri”, Heather Miller, PAC ~ April 17, 2007
Minirin Investigator Meeting, Bonita Spring’s, FL ~ May 4-5, 2007
AUA Annual Meeting, Anaheim, CA ~ May 19-24, 2007
“Preoperative Testing: Essential or Excessive”, Dr. Steven Johnson ~ June 19, 2007
Boehringer Ingelheim Advisory Board Meeting, Washington, DC ~ June 21, 2007
Organon National Advisory Board Meeting, Washington, DC ~ June 22-23, 2007
“Basics of Oncologic PET Imaging”, Dr. Jonathon White, MD. PhD ~ July 3, 2007
“Pediatric Sports Injuries”, Dr. Sandra Glasson ~ July 31, 2007
“Skin Cancer”, Dr. Kristen Martin ~ August 7, 2007
National Key Opinion Leader Advisory Board for Avodart, Washington, DC ~ August 24-25, 2007
“Minimally Invasive Spine Surgery”, Dr. Joseph Ong ~ September 11, 2007
“The Biology of Nodal Metastases in Renal Cell Carcinoma” , Dr. Christopher Woods ~ September 24-25,
2007
16
Gregg R. Eure, M.D.
“Prostate Cancer: Review and Update”, Dr. Raymond Lance ~ October 2, 2007
“Prostate Biopsy: How Many Cores and What to do with the Information”, Dr. Stephen Freedland ~
January 29, 2008
Cialis Speaker Training, Scottsdale, AZ ~ February 29, 2008
Joint Advocacy, Washington, DC ~ March 28-April 1, 2008
AUA Annual Meeting, Orlando, FL ~ May 16-22, 2008
Mid-Atlantic AUA, Cambridge, MD ~ August 24-28, 2008
ACADEMIC COURSES
Ultrasound Workshop, Dallas, Texas, January 10-11, 1992
Candela Lasertripsy Workshop, Portsmouth, Virginia, January 21, 1993
Genitourinary Pathology, February 19-24, 1993
Laparoscopic Urology 1993, April 22-23, 1993
Pathology and Uro-Radiation, Dearborn, MI, February 5-10, 1994
Uropathology, Washington, D.C., January 23-27, 1995
Pathology/Uroradiology, February 11-16, 1995
Transperineal Radioactive Seed Implantation Course, Endo-Surgery Institute, Cincinnati, Ohio,
March 13-14, 2000
Viadur Advisory Board and Workshop, Washington, DC, November 11, 2000
Faculty Training Program, “Hormonal Therapy in Prostate Cancer: Advancing the Continuum of
Androgen Suppression”, Boca Raton, Florida, March 9-11, 2001
Bayer’s Scientific Affairs Erectile Dysfunction Preceptership, Boston, MA, May 3-4, 2001
Speaker’s Training for Avodart, Las Vegas, NV ~ March 3-4, 2006
RESEARCH/RESEARCH ACTIVITIES
Research Chairman, Urology of Virginia Research Department
PRINCIPAL INVESTIGATOR-BPH
Lilly-ICOS – H6D-MC-LVHK – A Randomized, Double-Blind, Placebo-Controlled, ParallelDesign, Multicenter Study to Evaluate the Urodynamic Effects of Tadalafil Once a Day for 12
Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia – Open Trial
AMSPE0603-Greenlight - A Prospective Clinical Stud\y for GreenLight HPS™ in Treatment of
Obstructive Benign Prostatic Hyperplasia – Closed Trial
AMS055 – Thermatrx Evaluation of the Safety and Tolerability of TherMatrx TMx-2000™
BPH Thermotherapy System for the Treatment of Benign Prostatic. – Closed Trial
GSK DOP – UVA001 – A randomized, Placebo-controlled, Double-Blind Study of the Use of
Dutasteride for Improving Peri-Operative and Long-Term Outcomes of Photoselective
Vaporization of the Prostate. – Open Trial
17
Gregg R. Eure, M.D.
QLT, LTD – BPH Plus – QLT0074 BPH 003: A Phase II Randomized, Sham-Controlled, DoubleBlind, Dose-Finding Study to Access the Efficacy and Safety of Transurethral Photodynamic
Therapy with Lemuteporfin in Patients with Lower Urinary Tract Symptoms Due to Benign
Prostatic Hyperplasia – Closed Trial
Lilly-ICOS – H6D-MC-LVHG – A Randomized, Double-blind, Placebo-Controlled, Parallel-Design,
5-Group, Multinational Study to Evaluate the Efficacy, Dose Response, and Safety of Tadalafil
Once-a-day Dosing for 12 Weeks in Men with Signs and Symptoms of Benign Prostatic
Hyperplasia. - Closed Trial
Lilly-ICOS – H6D-MC-LVHG (Open-Label Extension Phase)– A Randomized, Double-Blind,
Placebo-Controlled, Parallel-Design, 5-Group, Multinational Study to Evaluate the Efficacy, Dose
Response, and Safety of Tadalafil Once-a-Day Dosing for 12 Weeks in Men With Signs and
Symptoms of Benign Prostatic Hyperplasia – Open Trial
SPECTRUM (Protocol SPI-153-06-1) – A Randomized, Double-Blind, Placebo-Controlled Trial
of the Safety and Efficacy of Ozarelix, in Patients with Lower Urinary Tract Symptoms (LUTS)
due to Benign Prostatic Hypertrophy (BPH) – Closed Trial
Evaluation of Transurethral Microwave Therapy in the treatment of benign prostatic hypertrophy
(BPH), THERMATRX, INC – September 1998 - Closed Trial
A Randomized Double-Blind, Placebo-Controlled, Two Year Parallel Group Study of the Efficacy
and Safety of GI198745 0.5 mg in the Treatment of and Prevention of Progression of Benign
Prostatic Hypertrophy, GLAXO WELLCOME, INC – October 1997 - Closed Trial
CO-INVESTIGATOR-BPH
PFIZER – Detrol/Flomax _ A Randomized, Double-Blind, Placebo Controlled, Four Arm (Placebo,
Tolterodine ER, Tamsulosin, and Tolterodine ER plus Tamsulosin) Study to Evaluate the Clinical
Efficacy and Safety of Tolterodine ER 4mg in Men who have frequency and urgency, with or
without Urinary urge Incontinence, with or without bladder outlet obstruction. – Closed Trial
A Post-Market Data Collection Clinical Study Evaluating the Uroflow and Symptoms Alleviation of
Water Induced Thermotherapy with the Thermoflex System, ARGOMED, December 1, 1999Closed Trial
Prostate Cancer Prevention Trial. To evaluate the administration of Proscar for the prevention of
prostate cancer, NATIONAL CANCER INSTITUTE/SWOG – Closed Trial (1993)
Two year, open extension to double-blind randomized placebo controlled multi-center study to
investigate the long-term effects of Finasteride in patients with BPH, Protocol #048-04-10/study
MK906, MERCK RESEARCH LABORATORIES – Closed Trial
PRINCIPAL INVESTIGATOR – Prostate Cancer
GSK AVO108943 – A Randomized, Double-Blind, Parallel Group Study Comparing Casodex
50mg plus Placebo to Casodex 50mg plus Dutasteride 3.5mg Administered for 18 months to Men
with Prostate Cancer Who Have Failed First-Line Andrgen Deprivation Therapy (Assessed by
18
Gregg R. Eure, M.D.
Rising PSA) Followed by Two-Year Extension Phase – Open Trial
GSK-REDUCE (Site 2): A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of
the Efficacy and Safety of Dutasteride 0.5 mg. Administered Orally Once Daily for Four Years to
Reduce the Risks of Biopsy –Detectable Prostate Cancer, Protocol GI198745/ARI40006-Open
Trial
REDEEM – GlaxoSmithKline – A Randomized, Double-Blind, Placebo-Controlled Trial Assessing
the Efficacy and Safety of Dutasteride in Extending the Time to Progression of Low-Risk,
Localized Prostate Cancer in Men who are Candidates for or Undergoing Expectant Management
AVO105948 - Open Trial
Protocol No. GTx-006-211: A Multicenter, Phase IIb, Four Arm, Dose Finding, Randomized,
Placebo-Controlle Study to Determine the Long Term Prostate Cancer Chemoprevention Efficacy
and Safety of 20 mg, 40 mg, & 60 mg. Daily of GTx-006 in Men with High Grade Prostate
Intraepithelial Neoplasia (PIN), Closed Trial
CO-INVESTIGATOR-Prostate Cancer
S000-Selenium and Vitamin E Cancer Prevention (SELECT), SWOG, Open Trial
Sanofi-Adventis: XRP6976J/3501 – A Multicenter, Open-Label, Randomized, Phase III Trial
Comparing Immediate Adjuvant Hormonal Therapy (ELIGARD® - leuprolide acetate) in
Combination with TAXOTERE® (docetaxel) Administered Every Three Weeks Versus Hormonal
Therapy Alone Versus Deferred Therapy Followed by the Same Therapeutic Options in Patients
with Prostate Cancer at High Risk of Relapse After Radical Prostatectomy. – Open Trial
CASODEX – AstraZeneca – A Randomized Double-Blind Comparative Trial of Bicalutamide
(Casodex) verses Placebo in Patients with Early Prostate Cancer. – Open Trial
COMPARE – Sanofi Synthelabo – Prospective, Observational Registry of The Management of
Men with Prostate Cancer and a Rising PSA Following Definitive Surgical or Radiological
Treatment of the Primary Tumor: PCA Registry COMPARE (Comprehensive, Observational,
Multicenter Prostate Adenocarcinoma Registry). – Closed Trial
GTX 300203 – A Randomized, Double-Blind, Placebo-Controlled, Multicenter Efficacy and Safety
Study of Toremifene Citrate for the Prevention of Bone Fractures in Men with Prostate Cancer on
Androgen Deprivation Therapy. - Closed Trial
GTX High Grade PIN – A Randomized, Double-Blind, Placebo-Controlled, Multicenter Efficacy and
Safety Study of Toremifene Citrate for the Prevention of Prostate Cancer in Men with High Grade
Intraepithelial Neoplasia (PIN) – Protocol No. G300104 - Open Trial
PCPT Long Term – S0437 – Prostate Cancer Prevention Trial (PCPT) Companion Long Term
Follow Up Study for Men Diagnosed with Prostate Cancer. – Open Trial
D9901: A Randomized, Double-Blind, Placebo Controlled Trial of Immunotherapy with Autologous
Antigen-Loaded Dendritic Cells (Provenge, APC8015) For Asymptomatic Metastatic HormoneRefractory Prostate Cancer Prostate Cancer, Dendreon Corporation, Open Trial
19
Gregg R. Eure, M.D.
“A Randomized, Double-Blind, Placebo-Controlled Trial of Immunotherapy with Autologus
Antigen-Loaded Dendritic Cells (Provenge, APC8015) for Asymptomatic Metastatic HormoneRefractory Prostate Cancer”, Protocol D9902, Dendreon Corporation, Open Trial
DENDREON9902B - “A Randomized, Double-Blind, Placebo Controlled Phase 3 Trial of
Immunotherapy with Autologus Antigen Presenting Cells Loaded with PA2024 (Provenge,
APC8015) in Asymptomatic Subjects with Gleason Sum ≤ 7, Metastatic, Androgen Independent
Prostatic Adenocarcinoma”, ProtocolD9902B, Closed Trial
DENDREONPB01 - An Open Label, Single Arm Trial of Immunotherapy with Autologous
Antigen Presenting Cells Loaded with PA2024 (APC8015F) for Subjects with Objective
Disease Progression and Disease-Related Pain on Trial D9902 Part B, Protocol PB01, Closed
Trial
D9903: A Phase II, Open Label, Single Arm Trial with Cryopreserved Autologous AntigenLoaded Dendritic Cells (APC8015F) for Hormone-Refractory Prostate Cancer Patients with
Objective Disease Progression, Dendreon Corporation, Closed Trial
Autologous PAP-loaded Dendritic Cell Vaccine (APC8015, Provenge) in Patients with NonMetastatic Prostate Cancer Who Experience PSA Elevation Following Radical Prostatectomy:
A Randomized, Controlled Double-Blind Trial. Protocol #Dendreon P-11, Dendreon
Corporation, Closed Trial
SWOG9917-L-Selenium Based Chemoprevention of Prostate Cancer Among Men with High
Grade Prostatic Intraepithelial Neoplasia, Closed Trial
JPR-3 “Phase III Randomized Trial Comparing Total Androgen Blockade Plus Pelvic Irradiation
in Clinical Adenocarcinoma of the Prostate, SWOG, Closed Trial
SWOG-JPR-7 – A Phase III Randomized Trial Comparing Intermittent Versus Continuous
Androgen Suppression for Patients with Prostate-Specific-Antigen Progression in the Clinical
Absence of Distant Metastases Following Radiotherapy for Prostate Cancer. – Closed Trial
SWOG9921 – Adjuvant Androgen Deprivation versus Mitoxantrone Plus Prednisone Plus
Androgen Deprivation in Selected High Risk Prostate Cancer Patients Following Radical
Prostatectomy, Phase III”, Closed Trial
“SWOG 0032, Phase II Evaluation of Early Oral Estramustine, Oral Etoposide and Intravenous
Paclitaxel in Combination with Hormone Therapy in Patients with High-Risk Metastatic
Adenocarcinoma of the Prostate.”, SWOG, Closed Trial
IDOO-156: A Randomized Phase III Trial Comparing Consolidation Therapy With or Without
Strontium-89 Following Induction Chemotherapy in Androgen-Independent Prostate Cancer,
SWOG, Closed Trial
RTOG P-0014 – A Phase III Randomized Study of Patients with High-Risk, Hormone-Naïve
Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus
Androgen Blockade With Delayed Chemotherapy, SWOG, Open Trial
20
Gregg R. Eure, M.D.
SWOG9346 – Intermittent Androgen Deprivation in Patients with Stage D2 Prostate Cancer,
Phase III, Open Trial
Prostate Cancer Intervention Versus Observation Trial (PIVOT): A randomized trial comparing
radical prostatectomy versus palliative expectant management for the treatment of clinically
localized prostate cancer, SWOG, September 1995 – Closed Trial
Repeat doses of Strontium – 89 adjuvant to maximum androgen blockade in newly diagnosed
stage D2 prostate cancer patients with bone metastases: A Phase II trial, MEDIPHYSICS, INC.
(Amersham Healthcare) December 1997 Closed Trial
A phase II double-blind comparison of safety and efficacy of ABT-627 versus placebo in subjects
with symptomatic hormone refractory prostate cancer (An oral pain medication for patients who
require Opioid Analgesia) (M96-500), ABBOTT LABORATORIES January 1998 – Closed Trial
Dose ranging study comparing best medical therapy with and without ABT-627 for the treatment of
men with asymptomatic hormone refractory adenocarcinoma of the prostate (M96-594), ABBOTT
LABORATORIES May 1998 – Closed Trial
An extension study to evaluate the safety and tolerability of ABT-627 in subjects with hormone
refractory adenocarcinoma of the prostate (M97-739) ABBOTT LABORATORIES May 1998 –
Closed Trial
A randomized double blind study comparative trial of Bicalutamide (Casodex) 150 mg versus
placebo each in combination with castration as second line therapy for patients with asymptomatic
metastatic prostate cancer. ZENECA PHARMACEUTICALS September 1998 – Closed Trial
Phase III randomized study of Abareliz-Depot versus Lupron with or without Casodex, PRAECIS
PHARMACEUTICALS, INC. December 1998 – Closed Trial
SWOG 9346 A Phase III trial of Intermittent Androgen Deprivation in patients with Stage D2
prostate cancer, SWOG October 1995 – Closed Trial
SWOG JPR.3 intergroup phase III randomized trial comparing total androgen blockade versus
CO- total androgen blockade versus total androgen blockade plus pelvic irradiation in clinical stage
T3-4, N0, M0 adenocarcinoma of the prostate, SWOG November 1996 – Closed Trial
SWOG 9205 Central prostate cancer serum repository protocol, May 1998 – Closed Trial
A randomized comparative trial of Casodex versus Flutamide used in combination with medical
castration in patients with untreated metastatic prostate cancer. Comparison of complete
androgen blockade with one of two LHRH agonists and one of two anti-androgens to determine
difference in toxicity and equivalence of efficacy between the respective combinations for men with
metastatic prostate cancer, ZENECA PHARMACEUTICALS – Closed Trial (1992)
A randomized double-blind controlled Phase III trial evaluating Zoledronate plus standard therapy
versus placebo plus standard therapy in patients with recurrent carcinoma of the prostate who are
asymptomatic with castrate levels of testosterone and have rising PSA levels without radiologically
evident metastatic disease, Novartis Pharmaceuticals-Closed Trial (1999)
21
Gregg R. Eure, M.D.
A multi-center open labeled trial to evaluate the safety and efficacy of Goserelin Acetate 10.8 mg
(Zoladex, ZD 9393) in subjects with advanced carcinoma of the prostate, ZENECA
PHARMACEUTICALS – Closed Trial (1995)
A randomized double blind comparative trial of Bicalutamide (Casodex) versus placebo in patients
with early prostate cancer, (705411/0023) ZENECA PHARMAECUTICALS – Closed Trial (1995)
Phase II evaluation of oral ALRT1057 in patients with advanced prostate cancer, LIGAND –
Closed Trial
An international phase II randomized double blind multi-center study to determine the safety and
efficacy of three different doses of Liarozole in patients with rising prostate specific antigen levels
after definitive treatment – LIA-INT –26, JANSSEN RESEARCH FOUNDATION – Closed Trial
A phase III open randomized multi-center trial to determine the efficacy and safety of the
combination of Liarozole with Prednisone in patients with relapsed hormone resistant prostate
cancer (LIA-INT-29), JANSSEN – Closed Trial
CO-INVESTIGATOR-Hot Flashes
A Phase III, Randomized, Multicenter, Placebo-Controlled, Double-Blind, Clinical Trial to Study
the Efficacy and Safety of CyPat® (Cyproterone Acetate [CA]) for the Treatment of Hot Flashes
Following Surgical or Chemical Castration of Prostate Cancer Patients and Its Impact on the
Quality of Life in these Patients" Protocol PCA-301, Closed Trial
An Open Label Extension of the Phase III, Randomized, Multicenter, Placebo-Controlled,
Double-Blind Clinical Trial to Study the Efficacy and Safety of Cypat ™ (Cyproterone Acetate
[CA]) for the Treatment of Hot Flashes Following Surgical or Chemical Castration of Prostate
Cancer patients and Its Impact on the Quality of Life in the these Patients. PCA-301A, Closed
Trial
CO-INVESTIGATOR QUALITY OF LIFE
Quality Of Life Assessment In Patients Before An After Treatment For Carcinoma Of The
Prostate, Devine-Tidewater Urology/Eastern Virginia Medical School, Open Trial
CO-INVESTIGATOR-Bladder Cancer
Phase IIb/III Chemoprevention Trial of Celecoxib to Prevent Recurrence of Superficial Bladder
Cancer, G. D. Searle NQ4-99-02-006, Closed Trial
SPECTRUM (Protocol SPI-611) – A Multicenter, Randomized Placebo-Controlled, DoubleBlind, Phase 3 Trial of Single-Dose Intravesical Eoquinâ as a Surgical Adjuvant Instilled in the
Early Postoperative Period iin Patients Undergoing Transurethral Resection for Noninvasive
Bladder Cancer – Closed Trial
Bioniche-HIS-0611-09692 – A Phase III, open-label, multicenter study of the efficacy and
safety of MCC in the treatment of patients with non-muscle invasive (superficial) bladder
cancer at high risk of progression and who are refractory to BCG. - Open Trial
22
Gregg R. Eure, M.D.
SWOG4B-95-1, "MVAC in Organ Confined Bladder Cancer Based on p53 Status.", Closed
Trial
“A National Phase II Trial of Intron, Interferon-Alfa 2b Plus BCG for treatment of Superficial
Bladder Cancer”, Closed Trial
A Multicenter Trial of Induction and 6 Courses of 3 Week Maintenance with BCG versus BCG
plus Interferon Alpha-2b (Intron A) in Superficial Bladder Cancer, Closed Trial
Phase III Randomized, Double-Blind Study of DFMO vs. Placebo in Low Grade Superficial
Bladder Cancer, Joint Effort of NCI, University of Wisconsin Comprehensive Cancer Center,
and ILEX Oncology, Inc., November 1998-Closed Trial
A Prospective, Longitudinal Study of PathVysionTM Bladder Test in Patients with Transitional
Cell Carcinoma of the Bladder, Closed Trial
Phase III randomized study of a single adjunctive instillation of intravesical AD32 (N
Trfluoroacetyladriamycin – 14 – valerate) versus no adjunctive therapy immediately following
transurethral resection in patients with multiple superficial (Ta/T1) bladder tumors, ANTHRA
PHARMACEUTICALS February 1997 – Closed Trial
BTA Trak and BTA Stat Assays in serial samples from subjects with newly diagnosed or a history
of bladder cancer, Protocol 9706-A, BARD DIAGNOSTICS March 1998 – Closed Trial
A randomized multi-center phase III clinical trial comparing BCI-immune activator with Adriamycin
for the treatment of refractory carcinoma in situ with or without cystoscopically unresectable
superficial bladder cancer (KLH study), November 1998 INTRACEL – Closed Trial
Comparative Phase II trial of intravesical Mitoxantrone (Novantrone versus no chemotherapy in Ta
G1 or G2 superficial bladder cancer (Dr. Sarosdy), IMMUNEX CORPORATION, November 1998 –
Closed Trial
SWOG 9460 Phase llb randomized chemoprevention trial of N – (4HPR) Retinamide (4HPR) in
transitional cell bladder carcinoma, SWOG, September 1997 – Closed Trial
SWOG 9455 Phase II study of 5FU infusion and alpha Interferon for treatment of advanced or
recurrent metastatic adenocarcinoma of the bladder, SWOG, November 1996 – Closed Trial
CO-INVESTIGATOR-Erectile Dysfunction
“A Randomized, Double-Blind, Parallel, Placebo Controlled Study in Men with Erectile
Dysfunction to Evaluate the Efficacy and Safety of Tadalafil When Sexual Attempts Occur at
Specific Time Points After Dosing.” Lily ICOS - Closed Trial
“An Open-Label, Multi-Center Single-Arm Study to Investigate the Safety, Tolerability and
Efficacy of Flexible Doses of Vardenafil Given on Demand in African American, Hispanic and
Caucasian Males with Erectile Dysfunction. Bayer Corporation Protocol No. 10786.” BayerClosed Trial
23
Gregg R. Eure, M.D.
A phase III long term open label flexible dose safety extension study of Apomorphine SL tablets in
the treatment of male erectile dysfunction (M97-682) – Closed Trial
Evaluation of the safety and efficacy of transurethral Alprostadil/Prazosin HC1 for the treatment of
erectile dysfunction (AP-02) VIVUS – Closed Trial
Long term evaluation of the safety and efficacy of transurethral Alprostadil/Prazosin in HC1 for the
treatment of erectile dysfunction (AP-04) VIVUS – Closed Trial
A phase III efficacy and safety study comparing escalating doses of Apomorphine or placebo in
the treatment of male erectile dysfunction (M97-763), TAP PHARMACEUTICAL – Closed Trial
A Phase III Efficacy and Safety Study of Three Fixed Doses of Apomorphine SL Tablets 2, 4, and
5 mg versus placebo in the treatment of male erectile dysfunction (M98-941), TAP
PHARMACEUTICAL, December 1998-Closed Trial
A Phase III Two-Year, Long Term, Open-Label, Flexible Dose, Safety Extension Study of
Apomorphine SL Tablets in the treatment of male erectile dysfunction (M98-936), TAP
PHARMACEUTICAL, December 1998-Closed Trial
CO-INVESTIGATOR-INTERSTITIAL CYSTITIS
MediciNova, Inc: Protocol No. MN-001-CL-002 – Phase II: A Phasse II, Randomized, DoubleBlind, Placebo-controlled, Multicenter Study to evaluate the Efficacy and Safety of Two Dosing
Regimens of MN-001 in Patients with Interstitial Cystitis. – Closed Trial
PRINCIPAL INVESTIGATOR-NOCTURIA
Ferring – FE992026 CS29 – A Randomized, Double-Blind, Placebo Controlled, Parallel group,
Multi-Center Study with a Double Blind Extension Investigating the Efficacy and Saftey of a
Fast Dissolving (“Melt”) Formulation of Desmopressin for the treatment of Nocturia in Adults –
Open Trial
PRINCIPAL INVESTIGATOR-INCONTINENCE/OVERACTIVE BLADDER
Study of Duloxetine HCl in Women of Different Demographic Characteristics and Comorbidities with Stress Urinary Incontinence: Evaluation of Efficacy and Safety. Protocol F1JUS-SBCD, Eli Lilly, Closed Trial
CO-INVESTIGATOR-INCONTINENCE/OVERACTIVE BLADDER
Astellas VICTOR 905-UC-008 – A Randomized, Double-Blind, Placebo-Controlled, Parallel
Group, Multicenter Safety and Efficacy, Phase 4 Study of VESIcare® (Solifenacin Succinate)
or Placebo in Combination with Tamsulosin HCL for the Treatment of Residual OAB
24
Gregg R. Eure, M.D.
Symptoms of Urgency and Frequency in Men. VICTOR: VESIcare® In Combination with
Tamsulosin in OAB Residual Symptoms. – Closed Trial
Pfizer-AMBER A6061023-1150 – A Phase 2, 8-week, Multicenter, Randomized Double-Blind,
Placebo Controlled, Parallel Group Study Evaluating the Efficacy, Tolerability and Safety of
[S,S]-Reboxetine (PNU-165442G) for Stress Urinary Incontinence in Women. – Closed Trial
Pfizer-Detrol/Flomax – A Randomized, Doule-Blind, Placebo-Controlled, Four Arm (Placebo,
Tolterodine ER, Tamsulosin, and Tolterodine ER plus Tamsulosin) Study to Evaluate the
Clinical Efficacy and Safety of Tolterodine ER 4mg in Men who have Frequency and urgentcy,
with or without Urinary urge incontinence, with or without bladder outlet obstruction. – Closed
Trial
PROTOCOL: F1J-MC-SBBO(a), INVESTIGATOR: PETER O. KWONG, M.D.
DRUG: DULOXETINE HCL, Closed Trial
A Patient Acceptability Study of a Once Daily Formulation of Tolterodine. A Phase IIB,
Open-Label, Single Arm Trial in Adults with Overactive Bladder and Symptoms of Urinary
Frequency, Urgency, and/or Urge Incontinence, Closed Trial
A Phase 2, 8-Week, Multi-Center, Randomized Double-Blind, Placebo Controlled, Parallel
Group Study Evaluating the Efficacy, Tolerability and Safety of [S,S]- Reboxetine (PNU165442G) for Stress Urinary Incontinence in Women. Closed Trial
A Phase II, 8-Week. Multi-Center, Randomized Double-Blind, Placebo Controlled, Parallel Group
Study Evaluating The Efficacy, Tolerability And Safety of (PNU-165442G) For Stress Urinary
Incontinence In Women. Closed Trial
CO-INVESTIGATOR-ANTIBIOTIC EFFECT TO SPERMATOGENESIS
Medicis Pharmaceutical Corp.- A Randomized, Double-Blind, Placebo-Controlled Study to
Examine the Effects of Minocycline Extended-Release Tablets on Spermatogensis in Human
Males – Closed Trial
CO-INVESTIGATOR-POST-VASECTOMY SEMEN SAMPLES
CONTRAVAC, INC – Study (Protocol #1) – Comparison of Hemacytometer Counts with
SpermCheck® Vasectomy Results of Post-Vasectomy Semen Samples. – Closed Trial
CO-INVESTIGATOR-RENAL CELL CARCINOMA
E2085 – A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib verses Sorafenib
verses Placebo in Patients with Resected Renal Cell Carcinoma – Open Trial
ECOG 2805 – A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib verses Sorafenib
verses Placebo in Patients with Resected Renal Cell Carcinoma – Open Trial
BIBLIOGRAPHY
Eure, Gregg R., Ladaga, Leopoldo, and Schellhammer, Paul F.: BCG Therapy for High Risk
25
Gregg R. Eure, M.D.
Stage T1 Superficial Bladder Cancer. Presented at the Annual American Urological Association
Meeting New Orleans, May 1990
Eure, Gregg R.: Bladder Neck Obstruction. Presented Mid-Atlantic Section, American Urological
Association, September, 1990
Schellhammer PF, Eure GR: The role of radical cystectomy in the management of high grade superficial
bladder cancer (Pa, P1, PIS, and P2). J Urol 1991 Nov;146(5):1378-9
Eure, Gregg R., Cundiff, Maria R., and Schellhammer, Paul F.: BCG Therapy for High Risk Stage T1
Superficial Bladder Cancer. The Journal of Urology, Vol. 147(2), 376-379, February, 1992
Benge, Bruce N., Eure, Gregg R., and Winslow, Boyd H.: Acute Bilateral Testicular Torsion in the
Adolescent. The Journal of Urology, Vol 148(1), 134, July 1992.
Miller, E. Bradley, Eure, Gregg R., and Schellhammer, Paul F.: Upper tract Transitional Cell Carcinoma
in Patients Treated with BCG; Annual Meeting May 1992, Mid-Atlantic Section, American
Urological Association September 1992
Miller, E. Bradley., Eure, Gregg R., Schellhammer, Paul F.: Upper Tract Transitional Cell Carcinoma
Following the Treatment of Superficial Bladder Cancer with BCG. Urology, Vol. 42(1), 26-30, July
1993.
Jordan GH, Whelan TV, Horstman WG, Tynes WV II, Robey EL, Eure, GR, Stecker JF Jr, Winslow BH,
Fabozzi SF, Schellhammer PF, and Lynch DF Jr.: Urology/Urinary System. The Pathophysiologic
Basis of Surgery, Chapter 23, pp. 581-601. Second Edition, Editor, J. Patrick Leary, Baltimore:
Williams & Wilkins, 1996
Eure, Gregg R., Schellhammer, Paul F.: Hormone Refractory Prostate Cancer. Topics in Clinical
Urology: Medical and Surgical Management of Prostate Cancer, 1996.
Albala DM, Turk TM, Fulmer BR, Koleski F, Andriole G, Davis BE, Eure GR, Kabalin JN, Lingeman J,
Nuzzarello J, Sundaram C: Periurethral transurethral microwave thermotherapy for the treatment
of benign prostatic hyperplasia: an interim 1-year safety and efficacy analysis using the Thermatrx
TMx-2000. Tech Urol. 2000 Dec;6(4):288-93
Albala DM, Fulmer BR, Turk TM, Koleski F, Andriole G, Davis BE, Eure GR, Kabalin JN, Lingeman JE,
Nuzzarello J, Sundaram C: Office Based Transurethral Microwave Thermotherapy Using The
TherMatrx TMx-2000. J Endourol 2002 Feb;16(1):57-61
Albala DM, Nuzzarello J, Kabalin JN, Andriole G, Eure GE, Davis BE, Lingeman JE: Transurethral
Microwave Thermotherapy (TUMT) Using The Thermatrx TMX-2000: A Quantitative
Assessment Of Patient Tolerance. Abstract #1165, American Urological Association Annual
Meeting, May 25-30, 2002, Orlando, Florida
Albala DM, Andriole G, Davis BE, Eure GR, Kabalin JN, Lingeman JE, Nuzzarello J, and Risk I:
Transurethral Microwave Thermotherapy (TUMT) Using The Thermatrx TMX-2000: Durability
Exhibited In A Study Comparing TUMT With A SHAM Procedure In Patients With Benign
Prostatic Hyperplasia (BPH), Abstract #1746, American Urological Association Annual
Meeting, Chicago, IL, April 26-May 1, 2003
26
Gregg R. Eure, M.D.
Eure, Gregg R.: Urology Times. BPH treatment Device may improve sexual function April 2005
Albala DM, Andriole G, Davis BE, Eure GR, Kabalin JN, Lingeman JE, Nuzzarello J, and Risk I:
Transurethral Microwave Thermotherapy (TUMT) Using The Thermatrx TMX-2000: Durability
For Treatment of Benign Prostatic Hyperplasia: Five Year Follow-Up Of Multicenter
Randomized Pivotal Trial October 2005
Eure, Gregg R.:PDR Disease Management Guide. Management of Patients with Benign Prostatic
Hyperplasia 2005
Eure GR, Lamont J, Plante M, Snyder, J:
Transurethral Microwave Thermotherapy (TUMT) Evaluation of the Thermatrx TMX-2000 Short
Treatment Protocol Procedural Tolerability and Short Term Efficacy in Patients with Benign
Prostatic Hyperplasia (BPH):Thermatrx EAU Abstract October 2006
Eure GR, Bepple J, Barone B:
A Randomized, Placebo-Controlled, Double-Blind Study of the use of Dutasteride for improving
peri-operative Outcomes of Photoselective Vaporization of the Prostate (DOP Trial) April, 2007
Eure, Gregg R: PDR Disease Management Guide: Management of Patients with Benign Prostatic
Hyperplasia 2008
OTHER PUBLICATIONS
News Article for The Beacon, a Virginian Pilot Supplement regarding prostate screenings. September
1998
“Urology Now”, Newsletter for referring physicians in the Virginia Beach area. October 1996.
27
Gregg R. Eure, M.D.

CURRICULUM VITAE GREGG ROUNTREE EURE, M.D., FACS

Transcription

Similar documents